SANTINI, DANIELE
 Distribuzione geografica
Continente #
AS - Asia 17.024
NA - Nord America 3.706
EU - Europa 1.763
OC - Oceania 68
SA - Sud America 52
AF - Africa 50
AN - Antartide 2
Totale 22.665
Nazione #
SG - Singapore 12.698
US - Stati Uniti d'America 3.559
HK - Hong Kong 2.628
CN - Cina 1.374
GB - Regno Unito 736
IT - Italia 316
DE - Germania 238
IN - India 140
CA - Canada 123
FI - Finlandia 74
NL - Olanda 72
AU - Australia 64
UA - Ucraina 53
JP - Giappone 46
ZA - Sudafrica 41
TR - Turchia 39
BR - Brasile 34
FR - Francia 34
CZ - Repubblica Ceca 32
PL - Polonia 29
ES - Italia 27
ID - Indonesia 22
MX - Messico 21
BE - Belgio 17
EE - Estonia 17
SE - Svezia 17
KR - Corea 15
CH - Svizzera 14
RU - Federazione Russa 11
LT - Lituania 9
SA - Arabia Saudita 9
AT - Austria 7
IL - Israele 7
TW - Taiwan 7
AR - Argentina 6
HU - Ungheria 6
PT - Portogallo 6
SK - Slovacchia (Repubblica Slovacca) 6
EG - Egitto 5
GR - Grecia 5
PE - Perù 5
RO - Romania 5
SI - Slovenia 5
AE - Emirati Arabi Uniti 4
BD - Bangladesh 4
CL - Cile 4
LU - Lussemburgo 4
AL - Albania 3
BA - Bosnia-Erzegovina 3
HR - Croazia 3
KW - Kuwait 3
NG - Nigeria 3
PH - Filippine 3
PK - Pakistan 3
TH - Thailandia 3
VN - Vietnam 3
AM - Armenia 2
AZ - Azerbaigian 2
BG - Bulgaria 2
BY - Bielorussia 2
CY - Cipro 2
DK - Danimarca 2
IE - Irlanda 2
IQ - Iraq 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
NZ - Nuova Zelanda 2
RS - Serbia 2
AF - Afghanistan, Repubblica islamica di 1
AQ - Antartide 1
BO - Bolivia 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
FK - Isole Falkland (Malvinas) 1
GS - Georgia del Sud e Isole Sandwich Australi 1
JM - Giamaica 1
JO - Giordania 1
MD - Moldavia 1
MS - Montserrat 1
MY - Malesia 1
NO - Norvegia 1
OM - Oman 1
PS - Palestinian Territory 1
SL - Sierra Leone 1
TO - Tonga 1
TV - Tuvalu 1
YE - Yemen 1
Totale 22.665
Città #
Hong Kong 2.610
Singapore 1.279
Ashburn 1.034
Boardman 801
Hefei 703
London 663
Shanghai 478
San Francisco 147
Los Angeles 136
Pune 102
Seattle 98
Munich 95
Toronto 88
Council Bluffs 72
Santa Clara 66
Washington 66
Rome 58
New York 45
Turku 41
Amsterdam 36
Tokyo 34
Helsinki 33
Melbourne 32
Brno 29
Warsaw 27
São Paulo 23
Chicago 22
Brooklyn 21
Naples 20
Milan 18
Boston 17
Dallas 17
Canberra 16
Secaucus 16
Sydney 16
West Jordan 16
Johannesburg 14
Mexico City 14
Montreal 14
Paris 13
Chennai 12
Hanover 12
Hasselt 12
St Louis 12
Stockholm 12
Charlotte 10
Haikou 10
Manchester 9
Oklahoma City 9
Phoenix 9
Riyadh 9
The Dalles 9
Hyderabad 8
Ankara 7
Guangzhou 7
Markham 7
Redmond 7
Sona 7
Bologna 6
Central 6
Frankfurt am Main 6
Mong Kok 6
Palermo 6
San Jose 6
Vienna 6
Atlanta 5
Baoding 5
Bratislava 5
Charleston 5
Florence 5
Lima 5
Ljubljana 5
Modena 5
New Taipei 5
San Pietro in Lama 5
Yeonsu-gu 5
Beijing 4
Budapest 4
Buffalo 4
Cleveland 4
Crawley 4
Haifa 4
Handan 4
Lincoln 4
Luxembourg 4
Miami 4
Mumbai 4
Padova 4
Reston 4
San Ferdinando Di Puglia 4
Shijiazhuang 4
Willisau 4
Wuhan 4
Andover 3
Antwerp 3
Athens 3
Barcelona 3
Bismarck 3
Brussels 3
Centurion 3
Totale 9.384
Nome #
A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: An open-label, non randomized, pilot study 216
Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference? 215
COX-2 expression in ampullary carcinoma: correlation with angiogenesis process and clinicopathological variables 200
ANGIOGENESIS AND ONCOGENES IN COLON CANCER 199
Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence 199
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 198
Early impairment of food intake in patients newly diagnosed with cancer 194
Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment 193
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases 191
S-Adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury 190
Repeated courses of radiation treatment in an HER2-positive breast cancer patient with diffuse brain metastases: A case report 189
COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features 189
Cyclooxygenase-2 overexpression is associated with a poor outcome in resected ampullary cancer patients 189
Designing a broad-spectrum integrative approach for cancer prevention and treatment 189
A new bioinformatic pipeline allows the design of small, targeted gene panels for efficient TMB estimation 188
Premetastatic niche: ready for new therapeutic interventions? 187
A key opinion leader interview with Prof D Santini: insight into cancer research. 185
COX-2 expression in lobular in situ neoplasia of the breast: correlation with histopathological grading system according to the Tavassoli classification 185
In Situ Identification of CD44+/CD24− cancer cells in primary human breast carcinomas 184
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation 184
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 184
A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss 183
Bone metastases in breast cancer: higher prevalence of osteosclerotic lesions 182
Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial 181
A prospective analysis of CT density measurements of bone metastases after treatment with zoledronic acid 180
Enoxiparin effects depend on body-weight and current doses my be inadequate in obese patients 178
Bisphosphonates: new antiangiogenic molecules in cancer treatment? 178
A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer 178
Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma 178
COX-2 expression of ampullary carcinoma: correlation with different histotypes and clinicopathological parameters 177
Prevention of radiotherapy-induced emesis 177
Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients 175
Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients 168
Gemcitabine-induced atrial fibrillation: A hitherto unreported manifestation of drug toxicity 166
NOD2/CARD15 polymorphisms impair innate immunity and increase susceptibility to gastric cancer in an Italian population 164
Complications of therapy in cancer patients: Case 3. Toxic epidermal necrolysis induced by oral phenobarbital and whole-brain radiotherapy in a breast cancer patient 163
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment 161
Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities 158
Docetaxel induced pericardial effusion 158
Longitudinal evaluation of vitamin D plasma levels during anthracycline- and docetaxel-based adjuvant chemotherapy in early-stage breast cancer patients 150
Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients 135
A giant sarcoma of the parotid gland: A case report and review of the literature 104
Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality? 104
'Internal bracing' surgery in the management of solid tumor metastases of the thoracic and lumbar spine 104
Prospective observational multicentric case-control study about 'fatigue' in patients with history of breast cancer 100
Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome 100
'All action no talk': the role of HER2/neu in adjuvant therapy choice for gastric cancer 97
Anestesia e malattie non comuni 96
Colorectal carcinomas and PTEN/MMAC1 gene mutations 94
Bilateral irreversible hearing loss associated with the combination of carboplatin and paclitaxel chemotherapy: a unusual side effect 92
'Old' and 'new' drugs for the treatment of cancer pain 92
Carcinoma of the Ampulla of Vater morphological and immunophenotypical classification predicts overall survival 91
Pancreatitis after percutaneous ethanol injection into HCC: a minireview of the literature 90
A prospective analysis of CT density measurements of bone metastases after treatment with zoledronic acid 90
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome 88
Abstract P5-04-13: Antibody-based therapy targeting integrin a5 is an effective strategy to treat experimental breast cancer bone metastasis 88
Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin 87
Biological effects of cabozantinib on osteosarcoma-bone microenvironment model 87
An increase of CA 19.9 as the first clinical sign of ileocecal valve metastasis from breast cancer 86
A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients 86
Idiosyncratic reaction after oxaliplatin infusion 85
Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial 85
A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer 85
Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours 85
Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions 85
Biological effects of cabozantinib on bone microenvironment 85
Body Mass Index and Impaired Fasting Blood Glucose as Predictive Factors of Efficacy in Cetuximab-Based Colorectal Cancer Treatment 85
Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw 84
Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients 84
Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis 83
In vivo effects of zoledronic acid on peripheral gamma delta T lymphocytes in early breast cancer patients 83
Liver cirrhosis after prolonged therapy with IFN-alpha plus interleukin-2 in a metastatic renal cancer long-term survivor 83
Atypical case of metastatic undifferentiated prostate carcinoma in a 36 years old man: clinical report and literature review 82
Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment 82
Cox-2 Expression in Different Histotypes of Ampullary Carcinoma 82
Different Levels of Alkaline Phospatase (ALP) in Multiple Myeloma (MM) and SOLID Tumors with BONE Lesions 82
Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan 81
Long non-coding RNA HSAT II as a new biomarker for the identification of high risk intraductal papillary mucinous neoplasms (IPMNs). 81
Atypical chronic head and neck pain: don't forget Eagle's syndrome 81
[Treatment of stage-I seminoma. Critical review] 80
Zoledronic acid induces a significant decrease of circulating endothelial cells and circulating endothelial precursor cells in the early prostate cancer neoadjuvant setting. 80
Apoptotic index or a combination of Bax/Bcl-2 expression correlate with survival after resection of pancreatic adenocarcinoma 80
Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature 77
Antitumor effect of cabozantinib in bone metastatic models of renal cell carcinoma 77
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 76
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies 75
Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells. 75
A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC) 74
Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes 74
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 73
Fatal thrombocytopenia and thrombocytopathia: An unusual onset of non small cell lung cancer 73
A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients 71
LIVER TOXICITY IN COLORECTAL CANCER PATIENTS TREATED WITH FIRST LINE FOLFIRI-CONTAINING REGIMEN: A SINGLE INSTITUTION EXPERIENCE 69
Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients 63
Pamidronate induces modifications of circulating angiogenetic factors in cancer patients 60
Classic Kaposi Sarcoma: to treat or not to treat? 58
Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6 58
Deep Learning Algorithm Trained with COVID-19 Pneumonia Also Identifies Immune Checkpoint Inhibitor Therapy-Related Pneumonitis 51
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib 50
Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial 50
Totale 12.241
Categoria #
all - tutte 245.688
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 245.688


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.010 0 4 5 8 73 10 15 4 42 20 23 806
2022/2023203 18 7 3 13 16 7 18 20 9 3 80 9
2023/20242.297 52 281 95 171 239 1.039 17 154 23 59 75 92
2024/202518.581 335 274 924 147 171 511 315 63 1.959 1.581 5.758 6.543
2025/2026707 707 0 0 0 0 0 0 0 0 0 0 0
Totale 22.798